Methods, compositions and articles of manufacture for contributing to the treatment of cancers
View Patent ↗Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ET B ) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.
1. A method of selectively increasing delivery of a chemotherapeutic agent to a prostate tumor comprising administering to a mammal in need thereof an IRL-1620 and a chemotherapeutic agent.
2. The method according to claim 1 , wherein said IRL-1620 is administered intravenously.
3. The method according to claim 1 , wherein the pharmacokinetic properties of said chemotherapeutic agent are not affected by said IRL-1620.
4. The method according to claim 1 , wherein said IRL-1620 and said chemotherapeutic agent are administered simultaneously.
5. The method according to claim 1 , wherein said IRL-1620 and said chemotherapeutic agent are administered sequentially.
6. The method according to claim 5 , wherein said IRL-1620 is administered at least 15 minutes before said chemotherapeutic agent.
7. The method according to claim 5 , wherein said IRL-1620 is administered about 15 minutes to about 120 minutes before said chemotherapeutic agent.
8. The method according to claim 5 , wherein said IRL-1620 is administered about 15 minutes to about 60 minutes before said chemotherapeutic agent.
9. The method according to claim 5 , wherein said IRL-1620 is administered about 15 minutes to about 30 minutes before said chemotherapeutic agent.
10. The method according to claim 1 , wherein said chemotherapeutic agent is adriamycin, camptothecin, carboplatin, cisplatin, daunorubicin, doxorubicin, alpha interferon, beta interferon, gamma interferon, interleukin 2, irinotecan, docetaxel, paclitaxel, topotecan, or mixtures thereof.
11. A method of selectively increasing delivery of a chemotherapeutic agent to a melanoma comprising administering to a mammal in need thereof an IRL-1620 and a chemotherapeutic agent.
12. The method according to claim 11 , wherein said IRL-1620 is administered intravenously.
13. The method according to claim 11 , wherein the pharmacokinetic properties of said chemotherapeutic agent are not affected by said IRL-1620.
14. The method according to claim 11 , wherein said IRL-1620 and said chemotherapeutic agent are administered simultaneously.
15. The method according to claim 11 , wherein said IRL-1620 and said chemotherapeutic agent are administered sequentially.
16. The method according to claim 15 , wherein said IRL-1620 is administered at least 15 minutes before said chemotherapeutic agent.
17. The method according to claim 15 , wherein said IRL-1620 is administered about 15 minutes to about 120 minutes before said chemotherapeutic agent.
18. The method according to claim 15 , wherein said IRL-1620 is administered about 15 minutes to about 60 minutes before said chemotherapeutic agent.
19. The method according to claim 15 , wherein said IRL-1620 is administered about 15 minutes to about 30 minutes before said chemotherapeutic agent.
20. The method according to claim 11 , wherein said chemotherapeutic agent is adriamycin, camptothecin, carboplatin, cisplatin, daunorubicin, doxorubicin, alpha interferon, beta interferon, gamma interferon, interleukin 2, irinotecan, docetaxel, paclitaxel, topotecan, or mixtures thereof.